Advertisement
Screener

Belite Bio, Inc (BLTE) Cash and securities

Belite Bio, Inc (BLTE) Cash and securities

  • Total cash · latest quarter (USD): Value (m); Formula and calculation Cash and cash equivalents plus current marketable securities. Period ending 2025-12-31..
  • Cash per share · latest quarter: Value (m); Formula and calculation Cash and cash equivalents plus current marketable securities / reported quarter-end common shares. Period ending 2025-12-31..

Cash and securities

Overview →

Financial period ending 2025-12-31; current quote (m). Amounts retain their stated periods and units.

MetricValueFormula and calculation
Total cash · latest quarter (USD)(m)Cash and cash equivalents plus current marketable securities. Period ending 2025-12-31.

Calculation unavailable: missing inputs remain (m).

Cash per share · latest quarter(m)Cash and cash equivalents plus current marketable securities / reported quarter-end common shares. Period ending 2025-12-31.

Calculation unavailable: missing inputs remain (m).

Calculation inputs

InputAmount with unitRaw financial data
Cash and equivalents352.93M USDCash and Cash Equivalents, at Carrying Value
Short-term securities(m)Debt Securities, Available-for-sale, Current
Cash and current securities(m)Cash and Cash Equivalents, at Carrying Value · Debt Securities, Available-for-sale, Current
Quarter-end shares(m)Common Stock, Shares, Outstanding

Calculated history

Changes compare with the next older row (previous quarter), unless explicitly labeled otherwise. Rolling 12-month growth compares two successive quarter-end rolling totals; it is not year-over-year growth.

Period endingTotal cashCash per shareCash and equivalents (USD)Short-term securities (USD)Quarter-end shares (shares)
2025-12-31(m)(m)$352.93M(m)(m)
2024-12-31$36.23M(m)$31.68M$4.55M(m)
2023-12-31(m)(m)$88.16M(m)(m)
2022-12-31(m)(m)$42.09M(m)(m)
2021-12-31(m)(m)$17.34M(m)(m)

(m) means missing inputs. Historical market-based ratios use the saved close on or immediately before period ending and that period’s reported shares; current quotes are not substituted. Five-year projections repeat historical CAGR, not analyst forecasts.